GlassScriptPhysician profile
Stephen Ray Halberg
NPI 1245877000
$3,370.47
in general payments reported to CMS, 2019-2025
24 companies · $874 in 2025
The $874 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $618 · 2023: $895 · 2024: $845 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $895.81 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $468.14 | 2022-2025 | |
| Abbvie INC. | $457.57 | 2022-2025 | |
| Novo Nordisk INC | $449.28 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $163.68 | 2022-2025 | Trelegy Ellipta |
| Eisai INC. | $123.28 | 2021-2022 | |
| Antares Pharma, INC. | $103.50 | 2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $96.00 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $81.13 | 2021-2023 | |
| Lilly USA, LLC | $79.46 | 2022-2025 | Mounjaro, Zepbound |
| Horizon Therapeutics Plc | $78.05 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $45.14 | 2023-2024 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $40.20 | 2022 | |
| Shield Therapeutics INC | $40.00 | 2024 | |
| Exact Sciences Corporation | $39.32 | 2024-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.22 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $31.83 | 2021-2022 | |
| Lundbeck LLC | $24.46 | 2024 | Rexulti |
| Merz North America, INC. | $23.95 | 2024 | |
| Dexcom, INC. | $22.39 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $19.99 | 2023 | Austedo |
| Viatris Specialty LLC | $17.68 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $17.61 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.78 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Halberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.